SENSEX NIFTY
Aug 22, 2012, 03.02 PM IST | Source: CNBC-TV18

No rivals for Suprax; Lupin eyes 22-25% domestic growth

Pharmaceutical company Lupin has become the latest entrant to the Nifty and will be indexed from September 28. The stock has been an outperformer over the months and S Ramesh, CFO of Lupin expects the company's domestic growth to be maintained at 22-25%.

Pharmaceutical company Lupin has become the latest entrant to the Nifty and will be indexed from September 28. The stock has been an outperformer over the months and S Ramesh, CFO of Lupin expects the company's domestic growth to be maintained at 22-25%.

In an interview with CNBC-TV18, Ramesh said he is not aware of any competition to the Suprax generic. He added, any other company filing for an approval of a similar generic version has to wait at least a couple of years to reach the market.

Further, Lupin is also looking forward to inorganic growth in Latin America and Russia. Ramesh is also hopeful of acquisitions ranging between USD 100 to 400 million.

Here is the edited transcript of the interview on CNBC-TV18.

Q: First your clarification on Suprax. Apparently a generic version is going to hit the market soon. Is that true, are you expecting some competition there?

A: I have actually not heard about it. In fact Suprax has been generic for quite some time, except that does not really have any competition. We do not know of anybody from India, from other parts of the world who have actually made a filing and even if somebody does that today, it will actually take a couple of years.

We believe that at least for the next couple of years, in the immediate line of sight, there will be no competition to Suprax.

Q: When do you expect to launch the Suprax drops?

A: We have not got approvals for that yet. So it could be possibly before the end of this fiscal.

Q: Can you update us on where things stand with the launch of generic Tricor?

A: We have actually settled with Abbot but, the terms of the settlement are actually confidential. We would not be in a position to talk about that. In any case we do not talk about impending launches. We could potentially be launching Tricor by the end of this fiscal.

Lupin stock price

On July 28, 2014, Lupin closed at Rs 1118.70, down Rs 10.15, or 0.9 percent. The 52-week high of the share was Rs 1139.00 and the 52-week low was Rs 742.30.


The company's trailing 12-month (TTM) EPS was at Rs 51.82 per share as per the quarter ended March 2014. The stock's price-to-earnings (P/E) ratio was 21.59. The latest book value of the company is Rs 155.59 per share. At current value, the price-to-book value of the company is 7.19.

1 2
READ MORE ON  Lupin, S Ramesh, Suprax, pharma, Nifty
Set email alert for

ADS BY GOOGLE

video of the day

Positive on PSU banks; NPA cycle may have peaked: Barclays

Explore Moneycontrol

Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.